Accumetrics (San Diego, CA) develops diagnostic tests for measurement of anti-platelet drug response closed a $28.8M Series D financing, Participants include Arnerich Massena & Associates, BBT Fund, Essex Woodland Health Ventures, RiverVest, PTV Sciences, KB Partners and Kaiser Permanente Ventures.

GraftCath (Coon Rapids, MN) a commercialization stage medical device company focused on reducing infections for dialysis patients closed a $11.8M Series D financing. Participants include Affinity Capital Management, Ascension Health Ventures, Cutlass Capital, Sapient Capital and Three Arch Partners.

Ascension Orthopedics (Austin, TX) developer of surgical implants for joint replacement, trauma and tissue regeneration closed a $21M Series D financing, Participants include return investor Frazier Healthcare Ventures.

Genizon Biosciences (Canada) is a therapeutic target and biomarker development stage company focused on Crohn’s disease, psoriasis, asthma and schizophrenia has closed a $31M Series D. Participants include BTF B.V.

ViOptix (Freemont, CA) developer of optical diffusion imaging and spectroscopy technology to enable non-invasive measurement of local tissue oxygen saturation closed a $12.2M Series D. Participants include Channel Medical Partners, Lincoln Funds International, Canadian Medical Discoveries Fund and Morningside Technology Ventures.

PeptImmune Inc. (Cambridge, MA) a clinical stage biotechnology company utilizing novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders such as pemphigus vulgaris and multiple sclerosis has closed on the first $8.2M traunche of a Series D financing. Participants include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical [...]

MAP Pharmaceuticals (Mountain View, CA) a product based biopharmaceutical focused on developing novel treatments for pediatric asthma and migraine therapy closed a $50M Series D financing. The deal was led by D.E. Shaw & Co. and was joined by Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital Partners, Bay City Capital and Skyline Ventures.

ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases and oncology with lead indications for inflammatory bowel disease and multiple sclerosis, closed a $29.9M Series D finanicing. The deal was led by the Glaxo Group Ltd. and was joined by Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.

Orqis (Lake Forest, CA) is developing devices to prevent or reverse the underlying disease progression of congestive heart failure has closed a $37.4M Series D financing. New investors include Wasatch Advisors, Cross Creek Capital and the Omega Fund along with Boston Scientific and Lighthouse Capital Partners.

TransOral Pharmaceuticals (Point Richmond, CA) a specialty pharmaceutical company CNS platform targeting insomnia and alcohol dependence, closed a $40M Series D financing. The deal was led by New Enterprise Associates additional participants included New Leaf Venture Partners, Montreux Equity Partners, InterWest Partners, Hamilton BioVentures, Vivo Ventures and Peninsula Equity Partners.